Sie wurde fr die Anwendung in der Behandlungskabine innerhalb professioneller kosmetischer Krperprotokolle entwickelt, insbesondere wenn die sichtbare Mobilisierung von Fettdepots untersttzt, das Erscheinungsbild von Cellulite-Haut verbessert und Bereiche mit lokalisierter Adipositt behandelt werden sollen
By merging clinical expertise with the convenience of telehealth, we provide a transparent path to better metabolic health
The SI increased by 29% at 24 h pi before returning to baseline level at the end of the study
Contact your GP or prescribing clinician if you experience: Gastrointestinal symptoms: Persistent or worsening heartburn, acid reflux, or chest pain despite taking omeprazole Severe or persistent nausea and vomiting that prevents adequate food or fluid intake Difficulty swallowing (dysphagia)this requires urgent referral (2-week wait) per NICE guidelines for suspected cancer Painful swallowing (odynophagia) Unexplained abdominal pain, particularly if severe or accompanied by fever Blood in vomit or black, tarry stools (melaena)these require urgent medical attention Persistent vomiting with weight loss, especially if you are aged 55 or over Unexplained iron-deficiency anaemia Signs of dehydration: Reduced urine output, dark-coloured urine, dizziness, or excessive thirst This is particularly important as Wegovy-related nausea combined with reduced acid-related symptoms might mask fluid intake issues Medication effectiveness concerns: Return of reflux symptoms after previously good control on omeprazole Inadequate weight loss response to Wegovy (less than 5% of initial body weight after 12 weeks at the maintenance dose of 2.4 mg or 1.7 mg), as per the Wegovy SmPC New or unusual symptoms that you suspect may be medication-related Before starting either medication: Inform your healthcare provider of all medications, supplements, and herbal remedies you take Discuss any history of pancreatitis, thyroid disease, or diabetic retinopathy (relevant for Wegovy) Mention any history of osteoporosis or fractures (relevant for long-term PPI use) NICE guidance recommends regular review of PPI therapy, typically after 48 weeks of treatment, and periodic attempts to step down to the lowest effective dose
Nucleic Acids Res (2012) 40(Database issue):D109114
